PHP
CLPT icon

Parkman Healthcare Partners’s ClearPoint Neuro CLPT Stock Holding History

Parkman Healthcare Partners’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,078
Closed -$89K – 87
2020
Q2 		$89K Hold
25,078
– – 0.03% 79
2020
Q1 		$90K Buy
+25,078
New +$123K 0.04% 66

Other funds holding CLPT

MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MWM
Merriman Wealth Management Seattle, Washington $2.4B AUM 13.66% 1-Year Est. Return
KMC
Kirr Marbach & Co Columbus, Indiana $594M AUM 34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return

Parkman Healthcare Partners's CLPT Position: Q3 2020 in Review

Parkman Healthcare Partners sold out of ClearPoint Neuro (CLPT) in Q3 2020, closing a stake of 25,078 shares — an estimated $89K sold.

Parkman Healthcare Partners first reported a position in CLPT in Q1 2020 and held it in 2 quarters. The position peaked at $90K in Q1 2020. 28 funds tracked by Wall St. Rank hold CLPT as of Q3 2020.

  • Parkman Healthcare Partners reported no remaining ClearPoint Neuro position as of Q3 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 25,078 ClearPoint Neuro shares in Q3 2020, an estimated $89K.
  • Parkman Healthcare Partners first reported a position in ClearPoint Neuro in Q1 2020 and held it in 2 quarters.
  • Parkman Healthcare Partners's ClearPoint Neuro position peaked at $90K in Q1 2020.
  • 28 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2020.

Based on Parkman Healthcare Partners's 13F filing for Q3 2020, filed 13 Nov 2020.